Nyxoah
Hypoglossal Nerve Stimulation Therapy for Obstructive Sleep Apnea
StartupNyxoah is a Tel Aviv-Yafo-based startup in the Health Tech & Life Sciences sector, established in 2008. Hypoglossal Nerve Stimulation Therapy for Obstructive Sleep Apnea. The company has raised a total of $270.7M across 10 funding rounds, currently at the Public stage. Nyxoah was founded by Robert Taub. Key investors include Undisclosed Investor(s), Cochlear Limited, ResMed, among 9 total investors. The company has 51-200 employees. Core technologies: Materials & Substances, Implants.
With $270.7M in total funding, Nyxoah is a Public-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Clinical Trial. The company holds 1 patent.
- StagePublic
- ProductClinical Trial
- ModelB2B
- Employees51-200
- HQTel Aviv-Yafo
- DistrictCenter District
- Last Round$27M
- Undisclosed Investor(s)
- Cochlear Limited
- ResMed
9 investors total
Robert TaubCo-founder & Executive Chairman
174 articles covered by sources including finance.yahoo.com,
www.medicaldevice-network.com,
european-biotechnology.com,
www.globenewswire.com,
financialpost.com.
What does Nyxoah do?
Nyxoah is a medical device company focused on the development and commercialization of hypoglossal nerve stimulation therapy for the treatment of obstructive sleep apnea (OSA). The company has developed a battery-free, leadless, minimally invasive neurostimulator capable of delivering bilateral hypoglossal nerve stimulation for patients with moderate to severe OSA who have failed at conventional positive airway pressure therapy. Nyxoahs therapy consists of a tiny neurostimulator that is implanted in the chin area in a minimally invasive surgery. The system, which is powered by a miniature external battery, is placed under the chin and stimulates the tongue nerve. In March 2019, Nyxoah received CE marking for its novel hypoglossal nerve stimulation therapy for treatment of obstructive sleep apnea. In January 2021, Nyxoah received CE mark magnetic resonance imaging (MRI) conditional labeling for the current Genio neurostimulation-based OSA therapy for treatment of obstructive sleep apnea.
How much funding has Nyxoah raised?
Nyxoah has raised $270.7M in total funding across 10 rounds. The company is currently at the Public stage. Key investors include Undisclosed Investor(s), Cochlear Limited, ResMed.
Who founded Nyxoah?
Nyxoah was founded in 2008 by Robert Taub (Co-founder & Executive Chairman).
What sector is Nyxoah in?
Nyxoah operates in Health Tech & Life Sciences, Medical Devices, Medical Treatment & Therapeutics, with core technologies in Materials & Substances, Implants. Target customers: Healthcare & Life Sciences, Healthcare, Providers, Patients.
Where is Nyxoah located?
Nyxoah is based in Yigal Alon Street 126, Tel Aviv-Yafo, Israel, Center District. The company also has offices abroad.